ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.
about
Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphomaAnaplastic lymphoma kinase: signalling in development and diseaseInflammatory myofibroblastic tumour of the gallbladderIntra-abdominal inflammatory myofibroblastic tumor: spontaneous regressionNovel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumorsALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitorsCrizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisInflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusionsA Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumorALK protein expression in rhabdomyosarcomas.Inflammatory myofibroblastic tumour of the tonsil: case report and literature review.Absence of anaplastic lymphoma kinase translocations in signet ring cell carcinomas of the upper gastrointestinal tract.Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series.Sinonasal Inflammatory Myofibroblastic Tumor with Anaplastic Lymphoma Kinase 1 Rearrangement: Case Study and Literature ReviewALK-rearrangements and testing methods in non-small cell lung cancer: a reviewInflammatory myofibroblastic tumor of the thigh without bone involvement: a case report.Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.Inflammatory myofibroblastic tumor of the small bowel: a case report.New therapeutic targets in soft tissue sarcoma.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor.Inflammatory myofibroblastic tumour in a female urethra: A rare benign lesion that mimics malignancy.Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.Inflammatory myofibroblastic tumour: report of a rare form with exclusive pleural involvementMaxillary sinus inflammatory myofibroblastic tumors: a review and case report.Inflammatory myofibroblastic tumors of the head and nec.Inflammatory myofibroblastic tumour of paranasal sinuses with fatal outcome: reactive lesion or tumour?ALK positive inflammatory myofibroblastic tumour of the pineal regionDifferential diagnosis of laryngeal spindle cell carcinoma and inflammatory myofibroblastic tumor--report of two cases with similar morphology.Abdominopelvic inflammatory myofibroblastic tumor that metastasized to the vertebrae and liver: A case report and review of the literatureMolecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangementArticular nodular fasciitis of the right shoulder joint: report of an unusual case with focus on immunohistochemical differential diagnosisSTUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: a preliminary clinicopathological study of nine cases and review of the literature.Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population.Progressive tumefactive fibroinflammatory lesion of the infratemporal fossa treated by radiation therapyInflammatory Myofibroblastic Tumor of the Liver: A Diagnostic Challenge.Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.
P2860
Q21285042-974F3030-F92C-45A4-A040-4190928EAC6BQ24312329-B9ACB646-F5B1-4EC7-93C6-4F96F3D63F1CQ24802581-A05BE66C-FC9D-4D8D-A3B9-AD738BFB638BQ26853086-50A58728-91F2-4E17-A7D4-E3A3F6D586DFQ27001114-85DB906D-4887-4B75-9CD5-9226C267AB21Q27310990-E46C046D-5F55-43A4-8289-8536866A8CE5Q27851589-CD29687B-B44A-41B1-9D82-E7E4892D1277Q27851671-97B955CA-8A84-4CE3-90B5-ED8834049456Q27853012-1D4EE5A1-0F87-438B-B529-F259123B1780Q27853092-296270B3-882F-4CDF-AC71-A32DD396F4F9Q28214316-675D63D0-FDD7-46E6-B452-AEE7F66A37AAQ31116403-4766E25C-1844-46B4-ACF7-D13686CA5F15Q33531356-9204576B-B6ED-4080-BD39-0087DCB3FDF3Q33557250-D9DB6B2D-5E91-45B1-A159-325F85992FD4Q33571326-790777E6-7304-4FD6-8BA6-36727DBA48D8Q33676389-7B18A56F-71EF-4EA3-8401-3041448C7719Q33776835-55EBC1CC-55D6-4C76-B43D-8C926702AAAAQ33965166-E3FF3217-31FA-414B-8DB3-6655BA60288CQ34028920-785012FD-BB2C-4C17-B892-37E5ED339DA8Q34135000-A2BE59C5-1ABD-41B0-94DB-E05514A38D34Q34267924-51A0A18F-E147-4D1A-81AC-EBAE335C2959Q34431889-14816C1D-5BF4-4388-A564-746D98ED199AQ34450749-A848BB94-1F29-446A-AEFA-5EC1E3F28733Q34602235-274AAF9B-D882-486B-8978-35A72DDA689DQ34624556-8494D6BD-B739-4C68-BE5D-E6F4CB9A5A3AQ34668858-3BEC273F-DFEE-4A95-9C12-EED328C21D65Q35119723-7019791A-EB38-4D27-AF77-AC6FDA081386Q35479102-6108DC30-9D61-491B-9912-76E62495D0D9Q35587007-69D99A94-226C-437E-9692-B9EB5EB72B84Q35588948-E8EFF946-E761-40CA-8EDA-DE6C0914DC3CQ35605292-84E4D3DC-4F06-40FE-8A8F-ABB6BFB98328Q35642057-6B60036A-94D3-4180-8E22-D7CFE8D1F40CQ35738399-D7631009-4817-48ED-ADF7-495BC73AA38CQ35741241-56894129-2C74-4156-BA4E-D5D568E624B7Q35741417-3DC56043-26A9-4F93-8B05-AEB5FFD44240Q35754685-241CDE25-86E4-4DF5-A0C6-CF3B77362F0DQ35871758-3F25FA3E-8517-483F-A329-08454D0CC7EDQ35887363-D25FB025-49F7-47AE-9693-9B7D456B85D3Q35905981-68BBFE5E-EBBB-4E6B-8B98-C72CA55976DAQ36092910-E6DB1587-334D-43EB-8C99-442823DC9542
P2860
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
ALK1 and p80 expression and ch ...... mmatory myofibroblastic tumor.
@en
type
label
ALK1 and p80 expression and ch ...... mmatory myofibroblastic tumor.
@en
prefLabel
ALK1 and p80 expression and ch ...... mmatory myofibroblastic tumor.
@en
P2093
P2860
P1433
P1476
ALK1 and p80 expression and ch ...... ammatory myofibroblastic tumor
@en
P2093
P2860
P2888
P304
P356
10.1038/MODPATHOL.3880352
P577
2001-06-01T00:00:00Z
P5875
P6179
1001859466